Carregando...
TMOD-06. HIGH INCIDENCE OF TUMORS AFTER TREATMENT WITH A DNA-ALKYLATING AGENT IN MOUSE STRAINS COMMONLY USED IN PRE-CLINICAL STUDIES
Glioblastoma (GBM) is commonly treated with the DNA-alkylating agent temozolomide (TMZ). Silencing O6-methylguanine-DNA methyltransferase (MGMT) by promoter hypermethylation predicts response to TMZ. Oral TMZ administration also affects tissues with low MGMT expression, such as bone marrow, resultin...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Principais autores: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217200/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.1119 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|